ALX Oncology Holdings Inc. (ALXO)
Largest Insider Buys in Sector
ALXO Stock Price History Chart
ALXO Stock Performance
About ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction …
Insider Activity of ALX Oncology Holdings Inc.
Over the last 12 months, insiders at ALX Oncology Holdings Inc. have bought $198,514 and sold $2.12M worth of ALX Oncology Holdings Inc. stock.
On average, over the past 5 years, insiders at ALX Oncology Holdings Inc. have bought $78.27M and sold $15.12M worth of stock each year.
Highest buying activity among insiders over the last 12 months: GARCIA PETER S (Chief Financial Officer) — $307,015. Lettmann Jason (CHIEF EXECUTIVE OFFICER) — $49,771. Hemrajani Rekha (director) — $46,404.
The last purchase of 30,000 shares for transaction amount of $46,404 was made by Hemrajani Rekha (director) on 2024‑12‑02.
List of Insider Buy and Sell Transactions, ALX Oncology Holdings Inc.
| 2024-12-02 | director | 30,000 0.0532% | $1.55 | $46,404 | -5.42% | |||
| 2024-08-14 | Sale | PRESIDENT & CSO | 1,937 0.0038% | $2.58 | $4,997 | 0.00% | ||
| 2024-08-14 | Sale | CHIEF MEDICAL OFFICER | 1,365 0.0027% | $2.58 | $3,522 | 0.00% | ||
| 2024-08-14 | Sale | SVP, FINANCE AND CAO | 564 0.0011% | $2.58 | $1,455 | 0.00% | ||
| 2024-07-11 | Sale | PRESIDENT & CSO | 20,000 0.0516% | $7.90 | $158,076 | 0.00% | ||
| 2024-07-05 | Sale | SVP, FINANCE AND CAO | 1,823 0.0033% | $5.50 | $10,025 | 0.00% | ||
| 2024-07-01 | Sale | PRESIDENT & CSO | 10,758 0.0204% | $5.82 | $62,599 | 0.00% | ||
| 2024-07-01 | Sale | CHIEF MEDICAL OFFICER | 3,273 0.0062% | $5.82 | $19,045 | 0.00% | ||
| 2024-07-01 | Sale | SVP, FINANCE AND CAO | 1,373 0.0026% | $5.82 | $7,989 | 0.00% | ||
| 2024-06-13 | CHIEF FINANCIAL OFFICER | 12,000 0.0229% | $8.53 | $102,338 | -77.37% | |||
| 2024-06-04 | Sale | PRESIDENT & CSO | 20,000 0.0387% | $8.43 | $168,652 | -75.81% | ||
| 2024-05-13 | Sale | CHIEF MEDICAL OFFICER | 12,000 0.0243% | $15.94 | $191,339 | -86.13% | ||
| 2024-05-06 | Sale | PRESIDENT & CSO | 20,000 0.0399% | $15.92 | $318,334 | -86.06% | ||
| 2024-04-16 | Sale | PRESIDENT & CSO | 50,000 0.0977% | $14.20 | $710,195 | -82.78% | ||
| 2024-04-04 | Sale | PRESIDENT & CSO | 20,000 0.0396% | $11.15 | $223,036 | -77.14% | ||
| 2024-03-14 | CHIEF EXECUTIVE OFFICER | 4,400 0.0085% | $11.31 | $49,771 | -74.64% | |||
| 2024-01-04 | Sale | SVP, Finance and CAO | 2,717 0.0057% | $13.60 | $36,957 | -31.58% | ||
| 2023-12-29 | Sale | President & CSO | 7,179 0.0144% | $15.04 | $107,972 | -37.84% | ||
| 2023-12-29 | Sale | Chief Medical Officer | 3,128 0.0063% | $15.04 | $47,045 | -37.84% | ||
| 2023-12-29 | Sale | Chief Financial Officer | 1,893 0.0038% | $15.04 | $28,471 | -37.84% |
Insider Historical Profitability
| Lettmann Jason | CHIEF EXECUTIVE OFFICER | 171620 0.3254% | $1.62 | 2 | 4 | +90.48% |
| GARCIA PETER S | CHIEF FINANCIAL OFFICER | 122348 0.232% | $1.62 | 2 | 8 | +90.48% |
| Hemrajani Rekha | director | 33000 0.0626% | $1.62 | 2 | 0 | +90.48% |
| Adelman Robert J | 5268325 9.9887% | $1.62 | 1 | 0 | +90.48% | |
| Graham G. Walmsley | director | 995000 1.8865% | $1.62 | 2 | 0 | +34.88% |
Institutional Investor Ownership
| venBio | $108.15M | 18.62 | 9.7M | 0% | +$0 | 38.37 | |
| Fidelity Investments | $83.88M | 14.44 | 7.52M | +0.67% | +$557,399.65 | 0.01 | |
| Redmile Group | $48.24M | 8.3 | 4.33M | +18.23% | +$7.44M | 0.49 | |
| Vivo Capital | $47.05M | 8.1 | 4.22M | 0% | +$0 | 4.1 | |
| Cormorant Asset Management Lp | $35.03M | 6.03 | 3.14M | 0% | +$0 | 1.63 |